The claim at the centre of a new paper from the University of Essex is arresting: that University of Essex intrabody research, using artificial intelligence, has produced a method for converting ordinary antibodies into fragments capable of working inside living human cells, where many of the biological processes behind Alzheimer’s, Parkinson’s, Huntington’s disease, and motor neurone disease begin. Whether that leads anywhere clinically is a much longer question, but the underlying methodology is worth examining on its own terms.
What the researchers actually did
Antibodies, as a rule, do their work outside cells. The problem for researchers who want to target disease-causing proteins inside cells is that conventional antibody fragments clump together in the cell’s internal environment and become useless. The Essex team, working with an international group, identified why: it comes down to electrical charge. The cell’s interior has a different charge profile from the extracellular space, and most antibody fragments carry the wrong charge to remain stable within it.
Armed with that insight, the researchers used protein redesign software developed by Nobel Prize winner David Baker and his group to systematically re-engineer antibody fragments so that they carry the correct charge and hold together reliably inside cells. The result, according to the paper published in Nature Communications, is a set of 672 converted antibodies, now redesigned as so-called intrabodies, each capable of binding to proteins associated with neurodegenerative disease inside living cells.
The research was funded by the MND Association and led by Dr Caitlin O’Shea and Dr Gareth Wright from the university’s School of Life Sciences. Dr O’Shea, who the paper identifies as specialising in MND and Parkinson’s disease, described the core finding in direct terms: ‘We looked at the properties of millions of antibodies and compared them with human proteins found inside the cell. From this we figured out that antibodies usually have the wrong charge to exist inside cells without sticking together. We used software developed by Nobel Prize winner David Baker and his group to redesign our antibody fragments, so they had the right charge and are super stable.’
University of Essex intrabody research: the case for repurposing existing science
One of the more pragmatic aspects of this work is that it does not require starting entirely from scratch. The researchers say the approach could allow scientists to find new applications for the vast library of antibodies already developed during decades of biomedical research, converting them into intrabodies rather than building entirely new molecules from the ground up.
Dr Wright, who directed the research, set out the public health context: ‘We’ve made intracellular antibodies that stick to proteins that cause neurodegenerative diseases such as Alzheimer’s, Parkinson’s, Huntington’s and motor neurone disease. These diseases can lead to cognitive impairment, forgetfulness, loss of muscle control and death. They affect over one million people in the UK alone, so they are a big public health concern. There are no cures for these diseases and finding molecules that interact with the proteins that cause them in their native environment is a major challenge in the medicine discovery process.’
That framing is accurate as far as it goes, but it is worth being precise about what the paper does and does not establish. The 672 intrabodies represent a laboratory advance: a proof that the charge-redesign method works at scale, and that the resulting fragments are stable and can bind their target proteins inside cells. The paper does not demonstrate clinical efficacy, safety in humans, or even animal model outcomes for any specific disease. Those steps remain ahead.
Following publication, the redesigned molecules will be made freely available to other scientists, which should at least allow independent groups to test the methodology and explore whether the intrabodies perform as described in their own experimental settings.
The gene therapy angle
The MND Association, which funded the work, responded positively. Its Chief Scientist, Dr Brian Dickie, said: ‘Dr Wright and his colleagues have made a significant advance in overcoming one of the key challenges that has impeded the development of antibodies as treatments for neurodegenerative diseases, such as MND. Their research findings provide optimism that a combination of this novel “intrabody” science with emerging gene therapy techniques may lead to new therapeutic strategies that can hit specific molecular targets within neurones.’
Dr Dickie’s framing is careful and worth noting: he says the findings ‘provide optimism’ that a combination of intrabody science and gene therapy techniques may lead to new strategies. That is a realistic representation of where this sits. Gene therapy delivery of intrabodies into neurones is itself an active and technically demanding field, and no such combined approach is described in the published work. The paper establishes the first element of that potential pipeline; the rest remains to be built.
What the University of Essex intrabody research does credibly demonstrate is a scalable, AI-assisted method for solving a longstanding charge-related barrier to working with antibodies inside cells. The next test will be whether independent laboratories, now that the molecules are freely available, can replicate the stability and binding results the Essex team reports in Nature Communications.
